Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Haematology"
DOI: 10.1111/ejh.13366
Abstract: Cytomegalovirus (CMV) is an opportunistic herpesvirus, and reactivation of infection is possible in immunocompromised patients. Historically, the risk for haematology patients is restricted to those treated with an allogeneic transplant or T‐cell depleting agents. Bortezomib… read more here.
Keywords: myeloma light; chain amyloidosis; bortezomib treatment; reactivation ... See more keywords
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils—A metric for predicting amyloid propensity
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0174152
Abstract: Background Monoclonal free light chain (LC) proteins are present in the circulation of patients with immunoproliferative disorders such as light chain (AL) amyloidosis and multiple myeloma (MM). Light chain-associated amyloid is a complex pathology composed… read more here.
Keywords: chain proteins; myeloma light; amyloid; light ... See more keywords